Freedom of Information Request: 0814 2020/21
I have a Freedom of Information request that I hope you’ll be able to help me with
Queen Elizabeth Hospital Birmingham:
- In the past 3 months, how many metastatic melanoma patients were treated by your Trust?
Dabrafenib – 0
Dabrafenib + Trametinib – 0
Densoumab – 0
Encorafenib + Binimetinib – 1
Ipilimumab – 0
Ipilimumab + Nivolumab – 6
Nivolumab – 0
Pembrolizumab – 2
Trametinib – 0
Vemurafenibb – 0
Vemurafenib + Cobimetinib – 0
Other active systemic anti-cancer therapy – 0
Palliative care only – 0
- Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:
Afatinib – 0
Atezolizumab monotherapy or combination – 0
Brigatinib – 0
Ceretinib – 0
Crizotinib – 0
Docetaxel monotherapy or combination – 0
Erlotinib – 0
Gefitinib – 0
Gemcitabine – 2
Nitendanib + docetaxel – 0
Nivolumab – 0
Osimertinib – 0
Paclitaxel – 1
Pembrolizumab monotherapy – 1
Pembrolizumab chemo in combination – 2
Pembrolizumab monotherapy – 0
Pemetrexed monotherapy or combination – 1
Ramucirumab – 0
Vinorelbine monotherapy or combination – 0
Other active systemic anti-cancer therapy – 0
Palliative care only – 2
- Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC ) with the following products?
Afatinib – 0
Atezolizumab monotherapy or combination – 0
Brigatinib – 0
Ceretinib – 0
Crizotinib – 0
Docetaxel monotherapy or combination – 0
Erlotinib – 0
Gefitinib – 0
Gemcitabine – 0
Nitendanib + docetaxel – 0
Nivolumab – 0
Osimertinib – 0
Paclitaxel – 0
Pembrolizumab monotherapy – 1
Pembrolizumab chemo in combination – 1
Pembrolizumab monotherapy – 0
Pemetrexed monotherapy or combination – 1
Ramucirumab – 0
Vinorelbine mono or combination – 0
Other active systemic anti-cancer therapy – 0
Palliative care only – 0
Heartlands, Good Hope and Solihull Hospitals (HGS):
- In the past 3 months, how many metastatic melanoma patients were treated by your Trust?
Not Applicable, Melanoma patients are not treated at HGS
Dabrafenib
Dabrafenib + Trametinib
Densoumab
Encorafenib + Binimetinib
Ipilimumab
Ipilimumab + Nivolumab
Nivolumab
Pembrolizumab
Trametinib
Vemurafenib
Vemurafenib + Cobimetinib
Other active systemic anti-cancer therapy
Palliative care only
- Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:
*Please see below response
Afatinib
Atezolizumab monotherapy or combination
Brigatinib
Ceretinib
Crizotinib
Docetaxel monotherapy or combination
Erlotinib
Gefitinib
Gemcitabine
Nitendanib + docetaxel
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pembrolizumab monotherapy
Pemetrexed monotherapy or combination
Ramucirumab
Vinorelbine monotherapy or combination
Other active systemic anti-cancer therapy
Palliative care only
- Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC ) with the following products?
*Please see below response
Afatinib
Atezolizumab monotherapy or combination
Brigatinib
Ceretinib
Crizotinib
Docetaxel monotherapy or combination
Erlotinib
Gefitinib
Gemcitabine
Nitendanib + docetaxel
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pembrolizumab monotherapy
Pemetrexed monotherapy or combination
Ramucirumab
Vinorelbine mono or combination
Other active systemic anti-cancer therapy
Palliative care only
*Please note for the above questions we are unable to determine from our Pharmacy systems if these patients have squamous or non-squamous histology, therefore we have provided the total number of metastatic NSCLC patients being treated at HGS.
Afatinib – 4
Atezolizumab monotherapy or combination – 7
Brigatinib – 0
Ceritinib – 2
Crizotinib – 0
Docetaxel monotherapy or combination – 5
Erlotinib – 0
Gefitinib – 5
Gemcitabine – 17
Nitendanib + docetaxel – 0
Nivolumab – 0
Osimertinib – 7
Paclitaxel – 1
Pembrolizumab monotherapy – 22
Pembrolizumab chemo in combination – 4
Pembrolizumab monotherapy – Duplicate – see answer above.
Pemetrexed monotherapy or combination – 15
Ramucirumab – 0
Vinorelbine monotherapy or combination – 4
Other active systemic anti-cancer therapy – 22
Palliative care only – Pharmacy system does not record to this detail
